New research in The Lancet suggests that statin underutilization might stem from unfounded safety fears rather than actual risk, after researchers found that 62 out of 66 the drugs’ package-listed adverse effects lack reliable evidence.
- Statins can reduce LDL-C by half and lower heart attack/stroke risk by 25% at generic costs of approximately $40 annually.
- However, many eligible patients refuse to start or discontinue therapy based on concerns about extensive side effect warnings.
- These listed side effects create usage barriers despite statins being considered “champions of preventive cardiology” with decades of accumulated safety data.
In an attempt to clear statins’ name, researchers analyzed data from 19 large RCTs to distinguish real statin-associated risks from coincidental symptoms, finding that…
- Only four statin side effects showed strong evidence: liver test changes, minor liver abnormalities, urine test changes, and tissue swelling.
- Muscle pain affected approximately 1% of statin users, with rare rhabdomyolysis (muscle tissue breakdown) requiring them to switch to other LDL-C lowering drugs.
- Small blood glucose increases occurred primarily in patients already near diabetes thresholds, though the CV benefits outweigh this risk even in diabetic patients.
- When it came to brain fog, the side effect was found in only 0.2% of statin users and 0.2% of placebo recipients in blinded trials.
Even with robust safety evidence, researchers emphasize that confusion and concern, not just in patients, but also in many doctors regarding potential statin side effects prevents people from starting or continuing therapy despite high cardiovascular risk.
- It’s also worth noting that since the COVID-19 pandemic, trust in physicians and broad guidelines has waned, so changing people’s minds on statins could be an uphill battle.
Given that the new PREVENT equation-based guidelines may recommend statins for 2.5M additional adults with elevated 30-year cardiovascular risk, addressing these safety misconceptions seems urgent for maximizing preventive cardiology’s population health impact.
The Takeaway
This comprehensive review casts statins in a new light, with many of the concerns around their side effects seemingly unfounded. That said, the cardiology community has a long way to go when it comes to educating patients about the pros and cons of this ubiquitous drug class.
